Allegra OTC Unlikely To Be In Sanofi-Aventis’ Future Plans
This article was originally published in The Tan Sheet
Executive Summary
Sanofi-Aventis reiterated its position that an Rx-to-OTC switch of Allegra (fexofenadine) would be the company's least-preferred option for the non-sedating antihistamine going forward